Subsidy Information and Financing Scheme MAFEpoprostenol (Veletri) Infusion 1.5 mg Treatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with co... See all × MAFEpoprostenol (Veletri) Infusion 1.5 mg Treatment of pulmonary arterial hypertension (idiopathic or heritable PAH or PAH associated with connective tissue diseases) in patients with WHO Functional Class III–IV symptoms
Drug Guidance for Subsidy 01/04/2020 Epoprostenol for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Epoprostenol (Veletri) 1.5 ... See all × 01/04/2020 Epoprostenol for treating pulmonary arterial hypertension The Ministry of Health’s Drug Advisory Committee has recommended: Epoprostenol (Veletri) 1.5 mg powder for solution for infusion for treating idiopathic or heritable pulmonary arterial hypertension (PAH) or PAH associated with connective tissue diseases, in patients with WHO Functional Class III–IV symptoms. Subsidy status REpoprostenol 1.5 mg powder for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication. NRMAF assistance does not apply to Veletri 0.5 mg vial or Flolan 0.5 mg and 1.5 mg vials.
Post Marketing Information DHCPL 30/08/2018 FLOLAN (epoprostenol) – Two different sterile diluents for FLOLAN will be temporarily available
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Veletri Infusion 1.5 mg Changi General Hospital National Heart Centre National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital
INTRAVENOUS Select a brand starting with the letter: V VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL [SIN15405P] VELETRI POWDER FOR SOLUTION FOR INFUSION 1.5MG/VIAL [SIN15406P]